Clinical trials: Age Related Maculopathy
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Age-Related Macular Degeneration
Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study
This study is a prospective, single centre, randomized, sham-controlled, double-masked, clinical trial which aims to investigate the effect of subthreshold nanosecond laser on disease progression in eyes with intermediate…
- Trial name
- LIANA (NCT05200624)
- Testing
- 2RT subthreshold nanosecond laser
- Where
- 4 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Center for Eye Research Australia
Age-related Macular Degeneration
Seven Year Update of Macular Degeneration Patients
The purpose is to assess long term vision outcomes and disease status in patients with age-related macular degeneration previously treated with ranibizumab as participants in the Phase 3 ANCHOR and MARINA Studies and the HORIZON…
- Trial name
- SEVEN UP (NCT01256827)
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Francisco
Neovascular Age-related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301…
- Trial name
- NCT03386474
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4…
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT06664502
- Testing
- EYE201
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- EyeBiotech Ltd.
Neovascular (Wet) Age-Related Macular Degeneration
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual…
- Trial name
- NCT07390253
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Age Related Macular Degeneration, Geographic Atrophy
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD.
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy, AMD, Age-related Macular Degeneration
- Trial name
- Project AMD (NCT04739319)
- Testing
- N/A Observational study
- Where
- Australia
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Macular Degeneration
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00089830
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Genaera Corporation
Age-Related Macular Degeneration, Macular Degeneration
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related…
- Trial name
- ATLAS (NCT01773954)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MidAtlantic Retina
Age-Related Macular Degeneration
Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment
The purpose of this study is to determine the effectiveness and safety of triamcinolone acetonide in patients with serous pigment detachment associated with age-related macular degeneration
- Trial name
- COAST_UA_AMD (NCT04292756)
- Testing
- Subtenon injection of 40 mg triamcinolone acetonide, Intravitreal injection of 4 mg triamcinolone acetonide, Visometry
- Where
- 4 sites in Ukraine
- Volunteers
- 63 people
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age-related Macular Degeneration
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.
- Trial name
- NCT01528605
- Testing
- low lutein, high lutein, lutein plus zeaxanthin
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Peking University
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Stargardt Disease, Diabetic Retinopathy
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
In this study, markers of oxidative stress will be measured in the aqueous humour of stargardt disease, age related macular degeneration and diabetic retinopathy patients compared to controls.
- Conditions
- Stargardt Disease, Diabetic Retinopathy, Macular Degeneration (Age Related)
- Trial name
- NCT02875704
- Testing
- Anterior Chamber (AC) Tap
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Johns Hopkins University
Age-related Macular Degeneration
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
- Trial name
- ReCLAIM-2 (NCT03891875)
- Testing
- Subcutaneous elamipretide through the elamipretide delivery system
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Stealth BioTherapeutics Inc.
Age-Related Maculopathy
Study Evaluating Genotypes Using Lucentis
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
- Trial name
- SEAGUL (NCT00474695)
- Testing
- Lucentis
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of Utah
Age-Related Macular Degeneration
Improving Function in Age-Related Macular Degeneration
This randomized, controlled clinical trial will test the efficacy of Problem-Solving Treatment (PST) to improve vision function in older persons with age-related macular degeneration (AMD).
- Trial name
- IF-AMD (NCT00572039)
- Testing
- PST, ST
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Thomas Jefferson University
Age-related Macular Degeneration
Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy
The purpose of this study is to define phenotypic variations in atrophic Age-Related Macular Degeneration (AMD) and to identify predictive factors for disease progression based on fundus autofluorescence imaging.
- Trial name
- NCT00393692
- Where
- 7 sites in Germany
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Age Related Macular Degeneration (AMD)
Development of Novel Clinical Endpoints in Intermediate AMD
Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR
- Trial name
- MACUSTAR (NCT03349801)
- Testing
- No intervention
- Where
- 20 sites in Denmark, France and 5 more
- Volunteers
- 718 people, healthy volunteers welcome
- Sponsor
- Frank G. Holz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.